CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

NG testWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug2220 Self-questionnary Wiki 1.00
drug387 Blood test Wiki 0.71
drug2663 Vitamin D Wiki 0.38

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne

Since the start of this epidemic, numerous clinical and fundamental studies have been conducted to best adapt the individual management of COVID-19 cases [1-6]. In parallel with this work, it is necessary to better understand the characteristics of the epidemic in the general population but also in the population working in healthcare settings more exposed to SARS-CoV-2. Seroprevalence studies are therefore particularly useful in order to understand the collective immunization rate and the factors that can explain this immunization.

NCT04416308 Coronavirus Diagnostic Test: NG test Diagnostic Test: Blood test Behavioral: Self-questionnary
MeSH:Coronavirus Infections

Primary Outcomes

Description: Rate of presence

Measure: rate of presence of anti-SARS-CoV-2 antibodies (Ig G _ Ig M) among employees working in a GHT Haute Bretagne health establishment.

Time: at inclusion visit

Secondary Outcomes

Description: Sensitivity

Measure: a) Validation of the Biotech NG test:

Time: at inclusion visit

Description: Specificity

Measure: a) Validation of the Biotech NG test:

Time: at inclusion visit

Description: agreement between observers (kappa coefficient)

Measure: a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgG

Time: at inclusion visit

Description: agreement between observers (kappa coefficient)

Measure: a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgM.

Time: at inclusion visit

Description: Demographic characteristics (age, sex)

Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function:

Time: At inclusion visit

Description: - Professional characteristics (establishment, profession, service).

Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function:

Time: At inclusion visit

Description: - Management of confirmed or probable COVID-19 patients

Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function:

Time: At inclusion visit

Description: - From contact with confirmed or probable COVID-19 professionals.

Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function:

Time: At inclusion visit

Description: - From contact in his personal circle with COVID-19 confirmed or probable persons.

Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function:

Time: At inclusion visit

Description: - Episodes of symptoms suggestive of COVID-19

Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function:

Time: At inclusion visit

Description: - The existence of a chronic immunomodulatory pathology

Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function:

Time: At inclusion visit

Description: - The existence of smoking

Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function:

Time: At inclusion visit

Description: - The use of materials adapted to good hygiene practices

Measure: c) Risk of presence of anti SARS-CoV-2 antibodies in function:

Time: At inclusion visit

Description: - Service organization

Measure: c) Risk of presence of anti SARS-CoV-2 antibodies in function:

Time: At inclusion visit

Description: depending on the work sector (COVID dedicated or not) and depending on the profession: - Rate of employees who changed their tobacco consumption

Measure: d) Description of the experience and behavioral changes related to the epidemic,

Time: at Day 0

Description: depending on the work sector (COVID dedicated or not) and depending on the profession: - Description of the reasons for modifying tobacco consumption

Measure: d) Description of the experience and behavioral changes related to the epidemic,

Time: at Day 0

Description: depending on the work sector (COVID dedicated or not) and depending on the profession: - Rate of employees who changed their alcohol consumption

Measure: d) Description of the experience and behavioral changes related to the epidemic,

Time: at Day 0

Description: depending on the work sector (COVID dedicated or not) and depending on the profession: - Description of the reasons for modification of alcohol consumption

Measure: d) Description of the experience and behavioral changes related to the epidemic,

Time: at Day 0

Description: depending on the work sector (COVID dedicated or not) and depending on the profession: - Rate of employees who have changed their eating habits

Measure: d) Description of the experience and behavioral changes related to the epidemic,

Time: at Day 0

Description: depending on the work sector (COVID dedicated or not) and depending on the profession: - Description of sleep changes

Measure: d) Description of the experience and behavioral changes related to the epidemic,

Time: at Day 0

Description: depending on the work sector (COVID dedicated or not) and depending on the profession: - Description of lived experience and perceived stress

Measure: d) Description of the experience and behavioral changes related to the epidemic,

Time: at Day 0

Description: For employees identified as COVID "certain or probable" * Percentage of employees with antibodies (IgG and IgM) against SARS CoV-2 on D30 and D90.

Measure: e) Evolution of seroprevalence over time:

Time: At Day30

Description: For employees identified as COVID "certain or probable" * Evolution of the kinetics of antibodies (IgG and IgM) against SARS CoV-2 on D30 and D90.

Measure: e) Evolution of seroprevalence over time:

Time: At Day 90

Description: For the random sample of employees with follow-up on D90: Percentage of employees with antibodies (IgG and IgM) against SARS CoV-2

Measure: e) Evolution of seroprevalence over time:

Time: At Day 90

No related HPO nodes (Using clinical trials)